Navigation Links
Watson Reaches Settlement with Teva Over Seasonale(R)
Date:5/7/2010

MORRISTOWN, N.J., May 7 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc. has reached a settlement with Teva Women's Health, Inc. on outstanding patent litigation related to Teva's Seasonale® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg) product.

On December 13, 2007, Teva filed a patent infringement lawsuit against Watson in the United States District Court for the District of New Jersey involving Watson's Quasense® product, which is a generic equivalent of Teva's Seasonale®.  Under terms of the settlement agreement, Teva has granted Watson a fully paid-up license to the U.S. patents covering Seasonale® and Watson will continue marketing its generic equivalent product Quasense® (levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg).  Watson further admits that the licensed patents are valid and enforceable.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance.  Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business.  These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report for the year ended December 31,2009.  Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms EVISTA(R) Patent Challenge
2. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 7th
3. Watson To Present at Bank Of America/Merrill Lynch 2010 Healthcare Conference
4. Watson Confirms Trilipix(R) Patent Challenge
5. Watson Confirms Rapamune(R) Patent Challenge
6. Watson Confirms Cenestin(R) Patent Challenge
7. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
8. Watson to Present at Barclays 2010 Global Healthcare Conference
9. Watson Receives FDA Approval for Generic Cardizem(R) LA
10. FDA Approves Watsons TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer
11. Watson Announces Actos(R) Patent Challenge Settlement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... 5, 2016  Balloon catheter is an innovative medical ... into the femoral artery in the leg or sometimes ... constricted blood vessels. These products are generally used to ... deposition of lipid substances in the blood vessel. In ... projected to expand at a CAGR of 3.8% during ...
(Date:12/5/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... to its previously-announced cash tender offers (the "Offers") ... below (collectively, the "Notes"), approximately $2.6 billion in aggregate ... not validly withdrawn on or prior to 5:00 p.m., ... today, December 5, 2016 (the "Early Tender Deadline"). ...
(Date:12/5/2016)... -- United Kingdom Ophthalmic Diagnostic Equipment Market Outlook ... "United Kingdom Ophthalmic Diagnostic Equipment Market Outlook to ... Kingdom Ophthalmic Diagnostic Equipment market. The report provides ... units) and average prices (USD) within market segements ... Systems, Corneal Topography Systems, Ophthalmoscopes, Perimeters, Auto Refractors ...
Breaking Medicine Technology:
(Date:12/6/2016)... , ... December 06, 2016 , ... ... launch of a Kickstarter crowd funding campaign ( http://kck.st/2g3a1so ) for the HealthyWatch, ... alerts and even taking an EKG from the watch while sharing these events ...
(Date:12/6/2016)... Arizona (PRWEB) , ... December ... ... product launched on Friday, November 25th, when SevenPoint2 released the much-anticipated HydroFX ... and all-new eye-catching label design. Featuring one of the world’s most powerful ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... CO. (PRWEB) , ... December 06, 2016 , ... Keeping ... that people choose gifts that are safe and age-appropriate for their recipients. This is ... time to reflect on the safety of items that would make good gifts for ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... fascinating recount of a powerful woman's story of sacrifice and enlightenment. ... of published author, Carolyn Fryer. Always looking for creative outlets, Carolyn gravitated toward ...
Breaking Medicine News(10 mins):